TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY

被引：0
作者：
Pietschmann, Peter [1 ]
机构：
[1] Med Univ Wein, Zentrum Physiol & Pathophysiol, Inst Pathophysiol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
来源：
JOURNAL FUR MINERALSTOFFWECHSEL | 2005年 / 12卷 / 01期
关键词：
D O I：
10.1359/JBMR.040920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：36 / 38
页数：3
相关论文
共 12 条
[1]   Summary of meta-analyses of therapies for postmenopausal osteoporosis [J].
Cranney, A ;
Guyatt, G ;
Griffith, L ;
Wells, G ;
Tugwell, P ;
Rosen, C .
ENDOCRINE REVIEWS, 2002, 23 (04) :570-578
[2]  
Dimai H P, 2002, Wien Med Wochenschr, V152, P596
[3]   Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate [J].
Eastell, R ;
Barton, I ;
Hannon, RA ;
Chines, A ;
Garnero, P ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) :1051-1056
[4]   Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents [J].
Hochberg, MC ;
Greenspan, S ;
Wasnich, RD ;
Miller, P ;
Thompson, DE ;
Ross, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04) :1586-1592
[5]   Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate:: a randomised, placebo-controlled study [J].
Hosking, D ;
Adami, S ;
Felsenberg, D ;
Andia, JC ;
Välimäki, M ;
Benhamou, L ;
Reginster, JY ;
Yacik, C ;
Rybak-Feglin, A ;
Petruschke, RA ;
Zaru, L ;
Santora, AC .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (05) :383-394
[6]   Users' Guides to the Medical Literature - XIX. Applying clinical trial results - B. Guidelines for determining whether a drug is exerting (more than) a class effect [J].
McAlister, FA ;
Laupacis, A ;
Wells, GA ;
Sackett, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1371-1377
[7]   Alendronate for the treatment of osteoporosis in men [J].
Orwoll, E ;
Ettinger, M ;
Weiss, S ;
Miller, P ;
Kendler, D ;
Graham, J ;
Adami, S ;
Weber, K ;
Lorenc, R ;
Pietschmann, P ;
Vandormael, K ;
Lombardi, A ;
Adachi, JD ;
Bell, N ;
Body, JJ ;
Castro, A ;
Daifotis, A ;
Felsenberg, D ;
Gilchrist, N ;
Hoffman, A ;
Maricic, M ;
Rizzoli, R ;
Silverman, S ;
Valeriano, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (09) :604-610
[8]  
Pietschmann P, 2004, J MINERALSTOFFWECHSE, V11, P24
[9]   Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study [J].
Rosen, CJ ;
Hochberg, MC ;
Bonnick, SL ;
McClung, M ;
Miller, P ;
Broy, S ;
Kagan, R ;
Chen, E ;
Petruschke, RA ;
Thompson, DE ;
de Papp, AE .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (01) :141-151
[10]   Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk [J].
Sarkar, S ;
Reginster, JY ;
Crans, GG ;
Diez-Perez, A ;
Pinette, KV ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (03) :394-401
12